Tom Dønnem

7.6k total citations · 1 hit paper
106 papers, 5.7k citations indexed

About

Tom Dønnem is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tom Dønnem has authored 106 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 46 papers in Molecular Biology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tom Dønnem's work include Cancer Immunotherapy and Biomarkers (24 papers), MicroRNA in disease regulation (17 papers) and Angiogenesis and VEGF in Cancer (17 papers). Tom Dønnem is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), MicroRNA in disease regulation (17 papers) and Angiogenesis and VEGF in Cancer (17 papers). Tom Dønnem collaborates with scholars based in Norway, United Kingdom and Singapore. Tom Dønnem's co-authors include Roy M. Bremnes, Lill‐Tove Busund, Samer Al‐Saad, Sigve Andersen, Khalid Al‐Shibli, Elin Richardsen, Thomas K. Kilvær, Mehrdad Rakaee, Magnus Persson and Helge Stenvold and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and PLoS ONE.

In The Last Decade

Tom Dønnem

106 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer

2010 525 citations Roy M. Bremnes, Tom Dønnem et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Dønnem Norway	42	3.1k	2.3k	1.8k	1.8k	1.6k	106	5.7k
Lill‐Tove Busund Norway	42	3.1k 1.0×	2.2k 0.9×	1.7k 1.0×	1.7k 1.0×	1.6k 1.0×	120	5.7k
Samer Al‐Saad Norway	36	2.3k 0.7×	1.7k 0.8×	1.2k 0.7×	1.3k 0.8×	1.3k 0.8×	66	4.3k
Florent Petitprez France	23	3.7k 1.2×	2.4k 1.1×	2.2k 1.3×	1.6k 0.9×	3.0k 1.9×	36	7.0k
Ichiro Kinoshita Japan	38	3.4k 1.1×	2.0k 0.9×	2.0k 1.2×	835 0.5×	1.7k 1.1×	148	5.8k
Helen K. Angell United Kingdom	22	4.0k 1.3×	2.1k 0.9×	1.9k 1.1×	1.4k 0.8×	2.7k 1.8×	40	6.5k
Juanita Lopez United Kingdom	28	2.6k 0.8×	1.9k 0.8×	1.3k 0.7×	821 0.5×	1.2k 0.8×	144	4.9k
Priti Lal United States	34	3.0k 1.0×	2.5k 1.1×	2.4k 1.4×	2.0k 1.1×	1.3k 0.9×	128	6.7k
Niels Reinmuth Germany	43	5.0k 1.6×	2.9k 1.3×	2.9k 1.6×	1.5k 0.9×	851 0.5×	196	7.9k
Young Kwang Chae United States	40	3.1k 1.0×	2.6k 1.1×	1.9k 1.1×	1.7k 1.0×	820 0.5×	274	6.4k
E. Gabriela Chiorean United States	42	4.7k 1.5×	2.1k 0.9×	1.5k 0.9×	1.7k 1.0×	1.7k 1.1×	209	7.1k

Countries citing papers authored by Tom Dønnem

Since Specialization

Citations

This map shows the geographic impact of Tom Dønnem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Dønnem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Dønnem more than expected).

Fields of papers citing papers by Tom Dønnem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Dønnem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Dønnem. The network helps show where Tom Dønnem may publish in the future.

Co-authorship network of co-authors of Tom Dønnem

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Dønnem. A scholar is included among the top collaborators of Tom Dønnem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Dønnem. Tom Dønnem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kilvær, Thomas K., Mona Irene Pedersen, Egil Støre Blix, et al.. (2024). High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC. Frontiers in Immunology. 15. 1504220–1504220. 1 indexed citations

Melbye, Hasse, et al.. (2024). Algorithm for predicting valvular heart disease from heart sounds in an unselected cohort. Frontiers in Cardiovascular Medicine. 10. 1170804–1170804. 4 indexed citations

Dønnem, Tom, et al.. (2023). Dying at “home” - a qualitative study of end-of-life care in rural Northern Norway from the perspective of health care professionals. BMC Health Services Research. 23(1). 1359–1359. 3 indexed citations

Richardsen, Elin, Sigve Andersen, Samer Al‐Saad, et al.. (2019). Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. Scientific Reports. 9(1). 10662–10662. 28 indexed citations

Rakaee, Mehrdad, Simin Jamaly, Erna‐Elise Paulsen, et al.. (2019). Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia. 21(3). 282–293. 119 indexed citations

Kilvær, Thomas K., Mehrdad Rakaee, Turid Hellevik, et al.. (2018). Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer. PLoS ONE. 13(2). e0192157–e0192157. 43 indexed citations

Paulsen, Erna‐Elise, Thomas K. Kilvær, Mehrdad Rakaee, et al.. (2016). Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer. 18(2). 220–233.e8. 72 indexed citations

Andersen, Sigve, Nora Ness, Yngve Nordby, et al.. (2016). Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome. Scientific Reports. 6(1). 33114–33114. 32 indexed citations

Andersen, Sigve, Elin Richardsen, Tom Dønnem, et al.. (2016). Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer – a multicenter (in situ hybridization) study. Scientific Reports. 6(1). 36573–36573. 14 indexed citations

10.

Dønnem, Tom, Sigurd M. Hald, Erna‐Elise Paulsen, et al.. (2015). Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(11). 2635–2643. 252 indexed citations

11.

Richardsen, Elin, Nora Ness, Samer Al‐Saad, et al.. (2015). The Prognostic Significance of CXCL16 and Its Receptor C-X-C Chemokine Receptor 6 in Prostate Cancer. American Journal Of Pathology. 185(10). 2722–2730. 31 indexed citations

12.

Andersen, Sigve, Samer Al‐Saad, Yury Kiselev, et al.. (2014). Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival. PLoS ONE. 9(9). e105038–e105038. 63 indexed citations

13.

Dønnem, Tom, Christopher G. Fenton, Thomas Berg, et al.. (2012). MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer. PLoS ONE. 7(1). e29671–e29671. 91 indexed citations

14.

Andersen, Sigve, Tom Dønnem, Samer Al‐Saad, et al.. (2011). Correlation and coexpression of HIFs and NOTCH markers in NSCLC.. PubMed. 31(5). 1603–6. 14 indexed citations

15.

Dønnem, Tom, Sigve Andersen, Samer Al‐Saad, et al.. (2011). Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size. Clinical Lung Cancer. 12(2). 106–115. 20 indexed citations

16.

Bremnes, Roy M., Tom Dønnem, Samer Al‐Saad, et al.. (2010). The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(1). 209–217. 525 indexed citations breakdown →

17.

Dønnem, Tom. (2009). 非小細胞肺癌におけるFGF2の予後因子としての意義--VEGFR-3またはPDGF-Bとの共発現は予後不良因子である. Journal of Thoracic Oncology. 3(2). 10–20. 1 indexed citations

18.

Al‐Shibli, Khalid, Samer Al‐Saad, Tom Dønnem, et al.. (2009). The prognostic value of intraepithelial and stromal innate immune system cells in non‐small cell lung carcinoma. Histopathology. 55(3). 301–312. 86 indexed citations

19.

Dønnem, Tom, Samer Al‐Saad, Khalid Al‐Shibli, et al.. (2008). Prognostic Impact of Platelet-Derived Growth Factors in Non-small Cell Lung Cancer Tumor and Stromal Cells. Journal of Thoracic Oncology. 3(9). 963–970. 96 indexed citations

20.

Al‐Saad, Samer, et al.. (2008). The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. British Journal of Cancer. 99(9). 1476–1483. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact